3b6e: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3b6e]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3B6E OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3B6E FirstGlance]. <br> | <table><tr><td colspan='2'>[[3b6e]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3B6E OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3B6E FirstGlance]. <br> | ||
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene>< | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | ||
<tr><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">IFIH1, MDA5, RH116 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">IFIH1, MDA5, RH116 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> | ||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3b6e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3b6e OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3b6e RCSB], [http://www.ebi.ac.uk/pdbsum/3b6e PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3b6e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3b6e OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3b6e RCSB], [http://www.ebi.ac.uk/pdbsum/3b6e PDBsum]</span></td></tr> | ||
<table> | </table> | ||
== Disease == | == Disease == | ||
[[http://www.uniprot.org/uniprot/IFIH1_HUMAN IFIH1_HUMAN]] Genetic variation in IFIH1 is associated with diabetes mellitus insulin-dependent type 19 (IDDM19) [MIM:[http://omim.org/entry/610155 610155]]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.<ref>PMID:16699517</ref> Note=IFIH1 is the CADM-140 autoantigen, involved in clinically amyopathic dermatomyositis (CADM). This is a chronic inflammatory disorder that shows typical skin manifestations of dermatomyositis but has no or little evidence of clinical myositis. Anti-CADM-140 antibodies appear to be specific to dermatomyositis, especially CADM. Patients with anti-CADM-140 antibodies frequently develop life-threatening acute progressive interstitial lung disease (ILD).<ref>PMID:19565506</ref> <ref>PMID:20015976</ref> | [[http://www.uniprot.org/uniprot/IFIH1_HUMAN IFIH1_HUMAN]] Genetic variation in IFIH1 is associated with diabetes mellitus insulin-dependent type 19 (IDDM19) [MIM:[http://omim.org/entry/610155 610155]]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.<ref>PMID:16699517</ref> Note=IFIH1 is the CADM-140 autoantigen, involved in clinically amyopathic dermatomyositis (CADM). This is a chronic inflammatory disorder that shows typical skin manifestations of dermatomyositis but has no or little evidence of clinical myositis. Anti-CADM-140 antibodies appear to be specific to dermatomyositis, especially CADM. Patients with anti-CADM-140 antibodies frequently develop life-threatening acute progressive interstitial lung disease (ILD).<ref>PMID:19565506</ref> <ref>PMID:20015976</ref> | ||
| Line 26: | Line 26: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Arrowsmith, C H | [[Category: Arrowsmith, C H]] | ||
[[Category: Berg, S Van Den | [[Category: Berg, S Van Den]] | ||
[[Category: Berglund, H | [[Category: Berglund, H]] | ||
[[Category: Busam, R D | [[Category: Busam, R D]] | ||
[[Category: Collins, R | [[Category: Collins, R]] | ||
[[Category: Dahlgren, L G | [[Category: Dahlgren, L G]] | ||
[[Category: Edwards, A M | [[Category: Edwards, A M]] | ||
[[Category: Flodin, S | [[Category: Flodin, S]] | ||
[[Category: Flores, A | [[Category: Flores, A]] | ||
[[Category: Graslund, S | [[Category: Graslund, S]] | ||
[[Category: Hammarstrom, M | [[Category: Hammarstrom, M]] | ||
[[Category: Holmberg-Schiavone, L | [[Category: Holmberg-Schiavone, L]] | ||
[[Category: Johansson, I | [[Category: Johansson, I]] | ||
[[Category: Kallas, A | [[Category: Kallas, A]] | ||
[[Category: Karlberg, T | [[Category: Karlberg, T]] | ||
[[Category: Kotenyova, T | [[Category: Kotenyova, T]] | ||
[[Category: Lehtio, L | [[Category: Lehtio, L]] | ||
[[Category: Moche, M | [[Category: Moche, M]] | ||
[[Category: Nilsson, M E | [[Category: Nilsson, M E]] | ||
[[Category: Nordlund, P | [[Category: Nordlund, P]] | ||
[[Category: Nyman, T | [[Category: Nyman, T]] | ||
[[Category: Persson, C | [[Category: Persson, C]] | ||
[[Category: | [[Category: Structural genomic]] | ||
[[Category: Sagemark, J | [[Category: Sagemark, J]] | ||
[[Category: Svensson, L | [[Category: Svensson, L]] | ||
[[Category: Thorsell, A G | [[Category: Thorsell, A G]] | ||
[[Category: Tresaugues, L | [[Category: Tresaugues, L]] | ||
[[Category: Weigelt, J | [[Category: Weigelt, J]] | ||
[[Category: Welin, M | [[Category: Welin, M]] | ||
[[Category: Antiviral defense]] | [[Category: Antiviral defense]] | ||
[[Category: Atp-binding]] | [[Category: Atp-binding]] | ||
| Line 69: | Line 69: | ||
[[Category: Phosphorylation]] | [[Category: Phosphorylation]] | ||
[[Category: Sgc]] | [[Category: Sgc]] | ||
Revision as of 11:32, 20 January 2015
Crystal structure of human DECH-box RNA Helicase MDA5 (Melanoma differentiation-associated protein 5), DECH-domain
| ||||||||||||
Proteopedia Page Contributors and Editors (what is this?)
Categories:
- Homo sapiens
- Arrowsmith, C H
- Berg, S Van Den
- Berglund, H
- Busam, R D
- Collins, R
- Dahlgren, L G
- Edwards, A M
- Flodin, S
- Flores, A
- Graslund, S
- Hammarstrom, M
- Holmberg-Schiavone, L
- Johansson, I
- Kallas, A
- Karlberg, T
- Kotenyova, T
- Lehtio, L
- Moche, M
- Nilsson, M E
- Nordlund, P
- Nyman, T
- Persson, C
- Structural genomic
- Sagemark, J
- Svensson, L
- Thorsell, A G
- Tresaugues, L
- Weigelt, J
- Welin, M
- Antiviral defense
- Atp-binding
- Dech
- Dexd/h rna-binding helicase
- Diabetes mellitus
- Host-virus interaction
- Hydrolase
- Ifih1
- Immune response
- Innate immunity
- Nucleotide-binding
- Nucleus
- Phosphorylation
- Sgc
